HUAWEI
During an exclusive launch event today at the Paris Convention Center, Huawei Consumer Business Group (BG) unveiled the HUAWEI P30 and HUAWEI P30 Pro. The HUAWEI P30 Series builds on the HUAWEI P Series DNA in design and photography and is the company’s most advanced series of smartphone cameras. These devices feature the innovative HUAWEI SuperSpectrum Sensor, an optical SuperZoom Lens, a new HUAWEI Time of Flight (ToF) Camera, and enhanced optical and AI image stabilization technology. With these revolutionary technologies, the HUAWEI P30 and HUAWEI P30 Pro capture incredible photos and videos in every scenario.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005752/en/
Richard Yu, CEO of Huawei Consumer BG, said, “the HUAWEI P30 Series is a fundamental breakthrough after decades of digital camera technology development; it will rewrite the rules and reshape everyone’s perception of mobile photography. Innovations such as the HUAWEI SuperSpectrum Sensor and SuperZoom Lens allow us to push the envelope of both photography and videography—a frontier long overdue for disruption. The HUAWEI P30 Series will set the pace for the next generation of smartphones by empowering people to capture the true beauty of the world around them through a device that fits in the palm of their hands.”
Rewriting the Rules of Photography for Stunning Professional-grade Pictures Every Time
Achieving a record-high overall DxOMark score of 112, the HUAWEI P30 Pro is equipped with a new Leica Quad Camera System, including a 40MP main camera with the HUAWEI SuperSpectrum Sensor, a 20MP ultra-wide angle camera, an 8MP telephoto camera, the HUAWEI ToF Camera and a 32MP front camera that takes selfies to a new level.
The 1/1.7-inch HUAWEI SuperSpectrum Sensor looks at light in a fundamentally new way. The RYYB HUAWEI SuperSpectrum Sensor deviates from the traditional RGGB Bayer filter by replacing green pixels with yellow pixels, yielding a high maximum ISO rating of 409,600 on the HUAWEI P30 Pro and 204,800 on the HUAWEI P30. This fundamental shift in sensor technology, combined with HUAWEI AIS, OIS and the HUAWEI P30 Pro’s f/1.6 wide aperture, delivers extraordinary photography and videography experiences across a wide range of scenarios and lighting conditions—including extreme low light—producing images with enhanced detail, color and clarity.
Through a new periscope design, the SuperZoom Lens supports high fidelity magnification of 5 times optical zoom, 10 times hybrid zoom and 50 times digital zoom. A prism element in the telephoto camera bends light at a 90-degree angle to maximize focal length while minimizing camera height, without disrupting device design.
Unique to the HUAWEI P30 Pro is a HUAWEI ToF Camera that captures depth-of-field information to deliver accurate image segmentation. Precise distance measurement allows for the simulation of multiple levels of bokeh. The Super Portrait feature captures even the smallest details, such as individual strands of hair. It combines depth information and proprietary algorithms to produce outstanding images with defocused backgrounds and highlights the subject of the image in any scenario.
Redefining Smartphone Videography
The HUAWEI SuperSpectrum Sensor enables spectacular low-light video capture so night scenes appear bright and highly detailed. HUAWEI AIS and OIS support stabilization for all video capture settings, resulting in a perfect, steady shot. Additionally, the SuperZoom Lens allows for crisp close-ups, while the AI Video Editor enables users to add background music and special effects to their videos, turning the HUAWEI P30 Series into a mobile production studio.
A Heritage of Stunning Design
The HUAWEI P30 Series design, created with a nine-layer nano optical color finish, is inspired by the unique color palette and pristine look of salt flats. The 6.47-inch HUAWEI P30 Pro and 6.1-inch HUAWEI P30 come in Breathing Crystal, Amber Sunrise, Aurora, Pearl White and Black. The FHD+ (2340x1080) Dewdrop Display features a tiny notch, providing maximum display area. The near bezel-less front glass houses an In-Screen Fingerprint sensor for quick and secure identity authentication. The HUAWEI P30 Pro also features HUAWEI Acoustic Display Technology that enables it to deliver high-quality audio through a sound emitting display.
Ultimate Innovation
The HUAWEI P30 and HUAWEI P30 Pro are packed with industry-leading features that set them apart in power, performance and efficiency:
- The HUAWEI P30 Series is powered by the 7nm Kirin 980 processor, which delivers ultimate performance, top-class efficiency and faster image recognition through its Dual-NPU AI processing power.
- The HUAWEI P30 Series features an Extendable Read-Only File System that improves system responsiveness. The latest EMUI 9.1 also supports HUAWEI Share OneHop for seamless file sharing between Huawei smartphones and Huawei laptops.
- The HUAWEI P30 Pro features a 4200mAh battery (typical value) and 40W HUAWEI SuperCharge that charges a device from zero to 70 percent in 30 minutes, keeping the device powered for more than a full day of intensive work.
- The HUAWEI P30 Pro features HUAWEI SuperCool technology to improve thermal performance, keeping the phone cool even during heavy use.
- The HUAWEI P30 Series is equipped with a suite of advanced wireless communications capabilities supporting Dual SIM and Dual VoLTE connectivity1 .
Pricing and Availability
Starting at EUR 799 and EUR 999 respectively, the new HUAWEI P30 and HUAWEI P30 Pro are immediately available globally.
About Huawei Consumer BG
Huawei’s products and services are
available in more than 170 countries and are used by a third of the
world’s population. Fifteen R&D centers have been set up in the United
States, Germany, Sweden, Russia, India and China. Huawei Consumer BG is
one of Huawei’s three business units and covers smartphones, PC and
tablets, wearables and cloud services, etc. Huawei’s global network is
built on almost 30 years of expertise in the telecom industry and is
dedicated to delivering the latest technological advances to consumers
around the world.
1 Specific features may vary depending on regional availability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190326005752/en/
Contact:
Mark Fowler +44 (0)208 811 2474 Huawei@racepointglobal.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom